PolarityTE, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PTE research report →
Range $1 – $1
Price Chart
About the company
Based in Salt Lake City, Utah, PolarityTE, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of regenerative tissue products and biomaterials. Its offerings serve the medical, biomedical engineering, and material sciences sectors across the United States.
- CEO
- Richard Hague
- IPO
- 1999
- Employees
- 42
- HQ
- Salt Lake City, UT, US
Get TickerSpark's AI analysis on PTE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.78M
- P/E
- 0.16
- PEG
- 0.00
- P/S
- 2.18
- P/B
- 0.10
- EV/EBITDA
- 1.00
- Div Yield
- 0.00%
- Gross Margin
- 24.32%
- Op Margin
- -3178.99%
- Net Margin
- 1254.42%
- ROE
- 56.95%
- ROIC
- 157.14%
Latest fiscal year · YoY change
- Revenue
- $814.00K-91.3%
- Gross Profit
- $198.00K-96.1%
- Op Income
- $-25,877,000
- Net Income
- $10.21M+136.2%
- EPS
- $1.49+116.9%
- OCF Growth
- +0.1%
- FCF Growth
- +0.5%
- 52W High
- $1.90
- 52W Low
- $0.20
- 50D MA
- $0.41
- 200D MA
- $0.67
- Beta
- 1.15
- RSI (14)
- 33
- Avg Volume
- 267.68K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
PolarityTE said it is advancing SkinTE with a covered DFU Phase 3 trial, a second randomized trial planned for early 2023, and cash expected to fund operations into Q1 2023.· August 11, 2022
- Covered DFU Phase 3 trial is underway: 10 subjects enrolled across 11 active sites, with up to 20 sites targeted by end of Q3.
- Company shifted from a broader VLU/DFU plan to pursuing a broad Wagner-grade DFU indication after FDA feedback.
- PolarityTE expects first 50 of 100 subjects enrolled by end of Q1 2023, interim data about six months later, and full enrollment by year-end 2023.
- Management said a second multicenter randomized controlled trial under the current IND is planned for early 2023 to support a BLA.
- Cash at June 30, 2022 was $20.5 million, which management said should fund activities into Q1 2023.
Operating costs and expenses decreased $3.6 million, or 35%, for the three months ended June 30, 2022 versus the same period in 2021. Cash used in operating activities was $8.2 million in Q2 2022, including $2.1 million of professional fees tied to a strategic transaction that did not materialize, $0.5 million of June offering costs, and $0.6 million of clinical trial expenses. Excluding those items, base operating cash used was $5 million, or $1.7 million per month, versus $4.1 million, or $1.4 million per month, in Q2 2021. As of June 30, 2022, cash and cash equivalents were $20.5 million and working capital was approximately $19.4 million. Management said this cash should fund business activities into the first quarter of 2023, and it wants base operational cash burn well below $2 million per month on average, excluding clinical trial and BLA-related costs.
Richard Hague focused on clinical execution and regulatory alignment, saying the company is prioritizing the fastest and most efficient path to get SkinTE back on the market. He highlighted the RMAT-enabled FDA dialogue, the decision to pursue a broad DFU indication, and the plan to work closely with FDA on the design of the second trial starting in early 2023. His tone was constructive and optimistic, while also signaling that the company is keeping strategic and synergistic options open.
Jacob Patterson emphasized cost reduction and liquidity. He said operating costs and expenses fell $3.6 million, or 35%, year over year in Q2, and detailed $8.2 million of operating cash use, including one-time items tied to a failed strategic transaction and the June offering. He noted $20.5 million in cash and cash equivalents and approximately $19.4 million of working capital at June 30, 2022, with runway into Q1 2023 and a goal of keeping base operating cash burn below $2 million per month on average.
There was no analyst Q&A; the operator noted there were no questions. The most notable discussion points were management’s clarification that FDA would not commit to the prior idea of combining a VLU trial with the covered DFU study, which led PolarityTE to refocus on a broad Wagner-grade DFU indication. Management also said data from the planned trials could potentially support an expedited pathway for other wound types later.
The call showed real clinical progress, with the covered DFU Phase 3 trial already enrolling and an FDA-aligned path emerging for a BLA-focused development plan. Management believes the new DFU-only strategy could be faster and less expensive than the earlier multi-wound approach, and they said recent industry interest has increased after the IND approval and RMAT designation.
The company still has limited cash runway, with funds expected to last only into Q1 2023, so additional financing will likely be needed. FDA did not provide the commitment management wanted for the earlier multi-wound plan, and the company has not yet secured agreement on the second trial design, leaving regulatory and execution risk still high.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 90.2%
- Shares Outstanding
- 7.38M
- Float Shares
- 6.65M
of shares held by institutions
1 13F filers
Buy/sell ratio 0.25. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| American Portfolios Advisors | 1 | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 26, 23 | Dyer Jeffrey Hansen | other | 42,986 |
| Jan 26, 23 | Dyer Jeffrey Hansen | other | 0 |
| Jan 26, 23 | Dyer Jeffrey Hansen | other | 0 |
| Jan 26, 23 | Dyer Jeffrey Hansen | other | 0 |
| Jan 26, 23 | Dyer Jeffrey Hansen | other | 0 |
| Jan 26, 23 | Dyer Jeffrey Hansen | other | 0 |
| Jan 26, 23 | Dyer Jeffrey Hansen | other | 0 |
| Jan 26, 23 | Dyer Jeffrey Hansen | other | 0 |
| Jan 26, 23 | Dyer Jeffrey Hansen | other | 0 |
| Jan 26, 23 | Dyer Jeffrey Hansen | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PTE coverage
Recent articles, reports, and earnings notes.
No research on PTE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PTE report →Pearson 2026 Nine Month Trading Update (Unaudited)
gurufocus.com · Oct 22
Pearson Interim Results for the six months to 30th June 2026 (Unaudited)
gurufocus.com · Jul 31
Commodities & Resources PTE Ltd. Announces Sale of Shares of Belmont Resources Inc.
globenewswire.com · May 13
Pioneering Technology Reports 2025 Q3 Financial Results
thenewswire.com · Aug 29
Commodities & Resources PTE Ltd. Announces Acquisition of Shares of Belmont Resources Inc. Pursuant to Private Placement
globenewswire.com · Jul 2
Commodities & Resources PTE Ltd. Announces Acquisition of Shares of Belmont Resources Inc. Pursuant to a Convertible Loan Agreement
globenewswire.com · Jul 2
Pioneering Technology Reports 2025 Q2 Financial Results
thenewswire.com · May 30
Momentum Builds for ScanTech AI Systems at PTE Madrid 2025 as Industry Embraces AI-Powered Security
globenewswire.com · Apr 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.